Abstract Details

Title Changes in Acute Migraine-specific Medications After Initiating Erenumab: Results from a Real-world Retrospective Cohort Study in the United States

Topic Headache

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 7-001

Objective

To examine real-world changes in acute migraine-specific medication (AMSMs) use among patients prescribed erenumab in the United States (US).

Background

Overuse of AMSMs can potentially complicate rather than support migraine management. Erenumab is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults that has been shown to significantly reduce use of AMSMs.

Design/Methods We conducted a retrospective cohort study using data from IQVIA’s open source pharmacy (LRx) and medical claims (Dx) databases. Patients 18 years or older were included if they had completed an adequate trial of erenumab (≥3 claims) between 5/1/18-4/30/19 (first claim was index date) with data continuity in the 12 months prior to and ≥6 months following the index date. Post-index change in AMSMs use (triptans and ergotamine derivatives used both pre-and-post index) included discontinuation (no refills for ≥60 days after last post-index fill) and change (post-pre index) in units (tablets/pills) filled.

Results

We identified 43,185 patients who received ≥3 doses of erenumab; female (85.8%), average (SD) age 47 (12.9) years. After initiation of Erenumab, AMSMs were discontinued in 8,556 of 23,222 patients with both pre- and post-index use (36.8%); triptans 8,021 of 22,338 patients (35.9%) and ergotamines 535 of 884 patients (60.5%). AMSM units changed in 18,571 of 23,222 patients (80.0%); triptans 18,034 of 22,338 patients (80.7%) and ergotamines 537 of 884 patients (60.7%) with an overall mean (SD) change of -1.2 (6.6) units for triptans and -0.4 (6.9) units for ergotamines.

Conclusions

In this US focused real-world study, a proportion of patients completing an adequate trial of erenumab discontinued and/or reduced consumption of their AMSMs. There is evidence that the benefits of erenumab seen in clinical trials, in terms of reductions in acute migraine-specific medications are being realized in real-world clinical practice.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Dawn C. Buse, PhD (Dawn C. Buse, PhD)	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
	No disclosure on file

��ɫ��

��ɫ��